hydroxychloroquine - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.11 [1.00, 1.23]< 10%22 studies (22/-)2.3 %highlow lowcrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical improvement 1.65 [0.52, 5.27]> 175%2 studies (2/-)80.0 %highnot evaluable lowimportant-
clinical improvement (14-day) 0.56 [0.13, 2.48]> 10%1 study (1/-)22.3 %some concernnot evaluable moderateimportant-
clinical worsening 1.16 [0.79, 1.69]< 15%4 studies (4/-)22.4 %highnot evaluable lowimportant-
death or ventilation 1.14 [1.03, 1.25]< 10%3 studies (3/-)0.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 1.42 [0.26, 7.76]> 10%1 study (1/-)65.5 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
ICU admission 0.83 [0.35, 1.95]< 10%1 study (1/-)66.8 %some concernnot evaluable moderatenon important-

-- safety endpoints 00

adverse events 1.35 [1.03, 1.76]< 10%7 studies (7/-)1.6 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 4 pathologies: 95,94,90,91 95, 90,94, 90, 91